Skip to main content
. 2023 Mar 7;24(6):5082. doi: 10.3390/ijms24065082

Figure 6.

Figure 6

OxLDL/LOX-1 prevents the enzalutamide effects in CRPC cell lines. (A) clonogenic assay of C4-2B and 22Rv1 cells transfected with a siRNA against LOX-1 or siRNA control and co-treated with enzalutamide [0–40 μM] and oxLDL 50 μg/mL oxLDL. (B) oxLDL prevents the effects of enzalutamide on AR and AR-V7 expression in CRPC cell lines. Western blot analysis of AR and AR-V7 on C4-2B and 22Rv1 cells co-treated with enzalutamide [20 μM]/oxLDL [50 μg/mL]. The data represent the means ± S.D. of three independent experiments analyzed by one-way analysis of variance and Dunnett’s post-test. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, ns: non-significant statistical difference).